251 related articles for article (PubMed ID: 23440003)
1. A review of minodronic acid hydrate for the treatment of osteoporosis.
Tanishima S; Morio Y
Clin Interv Aging; 2013; 8():185-9. PubMed ID: 23440003
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness of monotherapy and combined therapy with calcitonin and minodronic acid hydrate, a bisphosphonate, for early treatment in patients with new vertebral fractures: An open-label, randomized, parallel-group study.
Tanaka S; Yoshida A; Kono S; Ito M
J Orthop Sci; 2017 May; 22(3):536-541. PubMed ID: 28108224
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of minodronic acid hydrate in patients with steroid-induced osteoporosis.
Kitamura N; Shiraiwa H; Inomata H; Nozaki T; Ikumi N; Sugiyama K; Nagasawa Y; Karasawa H; Iwata M; Matsukawa Y; Takei M
Int J Rheum Dis; 2018 Apr; 21(4):813-820. PubMed ID: 26929019
[TBL] [Abstract][Full Text] [Related]
4. [Therapeutic agents for disorders of bone and calcium metabolism: Minodronic acid hydrate].
Miki T; Minamide T
Clin Calcium; 2007 Jan; 17(1):18-22. PubMed ID: 17211089
[TBL] [Abstract][Full Text] [Related]
5. [Minodronic acid hydrate as a new therapeutic agent for osteoporosis].
Chatani Y
Clin Calcium; 2005 Jan; 15(1):9-14. PubMed ID: 15632466
[TBL] [Abstract][Full Text] [Related]
6. Effect of daily oral minodronate on vertebral fractures in Japanese postmenopausal women with established osteoporosis: a randomized placebo-controlled double-blind study.
Matsumoto T; Hagino H; Shiraki M; Fukunaga M; Nakano T; Takaoka K; Morii H; Ohashi Y; Nakamura T
Osteoporos Int; 2009 Aug; 20(8):1429-37. PubMed ID: 19101754
[TBL] [Abstract][Full Text] [Related]
7. Once-yearly administered intravenous zoledronic acid for postmenopausal osteoporosis.
Woodis CB
Ann Pharmacother; 2008 Jul; 42(7):1085-9. PubMed ID: 18505912
[TBL] [Abstract][Full Text] [Related]
8. Effect of minodronic acid hydrate on hip geometry in Japanese women with postmenopausal osteoporosis.
Ito M; Sone T; Fukunaga M
J Bone Miner Metab; 2010 May; 28(3):334-41. PubMed ID: 19937358
[TBL] [Abstract][Full Text] [Related]
9. [Pharmacological profile and clinical efficacy of minodronic acid hydrate as a new therapeutic agent for osteoporosis].
Tanaka M; Mori H; Shimizu K; Toshiyuki ; Matsuoka ; Yamamotoya H; Minamide T; Mori M; Nozaki K; Usui T; Shimokawa K; Suzuki H; Aoyama K; Kimoto A; Sasamata M; Miyata K
Nihon Yakurigaku Zasshi; 2009 Sep; 134(3):149-57. PubMed ID: 19749488
[No Abstract] [Full Text] [Related]
10. [Fracture prevention in postmenopausal women with osteoporosis by an annual infusion of zoledronic acid].
Geusens PP; Lems WF
Ned Tijdschr Geneeskd; 2007 Jun; 151(26):1445-8. PubMed ID: 17633971
[TBL] [Abstract][Full Text] [Related]
11. [New development in bisphosphonate treatment. Review of effect on bone metabolism by minodronic acid in primary osteoporosis].
Fukunaga M
Clin Calcium; 2009 Jan; 19(1):63-73. PubMed ID: 19122266
[TBL] [Abstract][Full Text] [Related]
12. Nonvertebral fracture risk reduction with nitrogen-containing bisphosphonates.
Hochberg MC
Curr Osteoporos Rep; 2008 Sep; 6(3):89-94. PubMed ID: 18752769
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of once-yearly zoledronic acid in Japanese patients with primary osteoporosis: two-year results from a randomized placebo-controlled double-blind study (ZOledroNate treatment in Efficacy to osteoporosis; ZONE study).
Nakamura T; Fukunaga M; Nakano T; Kishimoto H; Ito M; Hagino H; Sone T; Taguchi A; Tanaka S; Ohashi M; Ota Y; Shiraki M
Osteoporos Int; 2017 Jan; 28(1):389-398. PubMed ID: 27631091
[TBL] [Abstract][Full Text] [Related]
14. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis.
Black DM; Delmas PD; Eastell R; Reid IR; Boonen S; Cauley JA; Cosman F; Lakatos P; Leung PC; Man Z; Mautalen C; Mesenbrink P; Hu H; Caminis J; Tong K; Rosario-Jansen T; Krasnow J; Hue TF; Sellmeyer D; Eriksen EF; Cummings SR;
N Engl J Med; 2007 May; 356(18):1809-22. PubMed ID: 17476007
[TBL] [Abstract][Full Text] [Related]
15. Zoledronic acid: a review of its use in the treatment of osteoporosis.
Deeks ED; Perry CM
Drugs Aging; 2008; 25(11):963-86. PubMed ID: 18947264
[TBL] [Abstract][Full Text] [Related]
16. Effects of bisphosphonates on fracture incidence and bone metabolism in rheumatoid arthritis patients in general practice taking long-term corticosteroid therapy: a retrospective study.
Katayama K; Matsuno T
Clin Drug Investig; 2008; 28(3):149-58. PubMed ID: 18266400
[TBL] [Abstract][Full Text] [Related]
17. Randomized head-to-head comparison of minodronic acid and raloxifene for fracture incidence in postmenopausal Japanese women: the Japanese Osteoporosis Intervention Trial (JOINT)-04.
Uemura Y; Sone T; Tanaka S; Miyazaki T; Tsukiyama M; Taguchi A; Soen S; Mori S; Hagino H; Sugimoto T; Fukunaga M; Ohta H; Nakamura T; Orimo H; Shiraki M;
Curr Med Res Opin; 2020 Nov; 36(11):1847-1859. PubMed ID: 32870712
[TBL] [Abstract][Full Text] [Related]
18. Intermittent minodronic acid treatment with sufficient bone resorption inhibition prevents reduction in bone mass and strength in ovariectomized rats with established osteopenia comparable with daily treatment.
Kimoto A; Tanaka M; Nozaki K; Mori M; Fukushima S; Mori H; Shiroya T; Nakamura T
Bone; 2013 Jul; 55(1):189-97. PubMed ID: 23486179
[TBL] [Abstract][Full Text] [Related]
19. Effects of once-monthly minodronate versus risedronate in osteoporosis patients with rheumatoid arthritis: a 12-month randomized head-to-head comparison.
Kumagai K; Harigane K; Kusayama Y; Tezuka T; Choe H; Inaba Y; Saito T
Osteoporos Int; 2018 Jul; 29(7):1637-1642. PubMed ID: 29574518
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and Safety of Zoledronic Acid for Treatment of Postmenopausal Osteoporosis: A Meta-Analysis of Randomized Controlled Trials.
Wang C
Am J Ther; 2017; 24(5):e544-e552. PubMed ID: 26938765
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
